Impact of alopecia areata on quality of life assessed by the dermatology life quality index: a cross-sectional study at a tertiary care hospital in Peshawar
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20262233Keywords:
Alopecia areata, Quality of life, DLQI, Cross-sectional study, PakistanAbstract
Background: Alopecia areata is a long-term autoimmune disease that causes non-scarring hair loss. It manifests as distinct, circular or oval patches on scalp or other parts of the body having hair. It happens when the immune system attacks anagen-phase hair follicles, abruptly stopping hair growth, affecting people of all ages. This study is designed to assess the impact of alopecia areata on quality of life using the dermatology life quality index (DLQI) among patients in a tertiary care hospital in Peshawar.
Methods: This descriptive cross-sectional study was conducted at the dermatology outpatient department of Hayatabad Medical Complex, Peshawar, from January 2025 to June 2025. Ninety-two patients aged 18–65 years with clinically diagnosed alopecia areata were enrolled. Quality of life was assessed using the validated Urdu version of the DLQI. Data were analyzed using statistical package for the social sciences (SPSS) version 28. The chi-square test was used to assess the relationship between DLQI scores and demographic or clinical factors.
Results: The mean age of participants was 31.4±10.7 years, with 59% males. The mean DLQI score was 9.6±5.2, indicating a moderate impact on quality of life. Higher DLQI scores were significantly associated with female gender (p=0.03), disease duration greater than one year (p=0.02) and severe clinical disease (p<0.001).
Conclusion: Alopecia areata has a significant negative impact on patients’ quality of life, among females having long-standing or severe disease. Routine use of DLQI may help identify patients who require additional psychological support alongside dermatologic treatment.
References
Benigno M, Anastassopoulos KP, Mostaghimi A, Udall M, Daniel SR, Cappelleri JC, et al. A large cross-sectional survey study of the prevalence of alopecia areata in the United States. Clin Cosmet Investig Dermatol. 2020;13:259-66.
Ahmed M, Ayub N, Hamza M, Nafisa A, Zaidi DZ, Zaidi IZ. Dermoscopic and clinical features of alopecia areata in Pakistani patients: a cross-sectional study. J Rawalpindi Med Coll. 2024;28(4).
Sy N, Mastacouris N, Strunk A, Garg A. Overall and racial and ethnic subgroup prevalences of alopecia areata, alopecia totalis, and alopecia universalis. JAMA Dermatol. 2023;159(4):419-23.
Saleem A, Khan M, Mashori GR, Samdan IA, Kazmi SA. Comparison of effectiveness of topical tacrolimus and betamethasone with soft paraffin in the treatment of patchy alopecia areata. Pak J Med Sci. 2009;25(5):833-6.
Salam S, Rafiq Z, Aziz N, Anwar A. Frequency of alopecia areata with other autoimmune disorders. Prof Med J. 2022;29(2):227-31.
Al-Mutairi N, Eldin ON. Clinical profile and impact on quality of life: seven years’ experience with patients of alopecia areata. Indian J Dermatol Venereol Leprol. 2011;77(4):489-93.
Jameel K, Ejaz A, Sohail M, Rahman SB. Value of transverse section scalp biopsy in alopecia areata: a clinicopathological correlation. J Coll Physicians Surg Pak. 2008;18(6):338-41.
Khalid A, ur Rehman F, Javed A. Evaluation of serum vitamin D levels in patients with alopecia areata. Pak Armed Forces Med J. 2022;72(6):2193.
Chaitra V, Rajalakshmi T, Kavdia R. Histopathologic profile of alopecia areata in Indian patients. Int J Trichol. 2010;2(1):14-7.
Qi S, Xu F, Sheng Y, Yang Q. Assessing quality of life in alopecia areata patients in China. Psychol Health Med. 2015;20(1):97-102.
Masmoudi J, Sellami R, Ouali U. Quality of life in alopecia areata: a sample of Tunisian patients. Dermatol Res Pract. 2013;2013:983804.
Rafique R, Hunt N. Experiences and coping behaviours of adolescents in Pakistan with alopecia areata: an interpretative phenomenological analysis. Int J Qual Stud Health Well-being. 2015;10(1):26039.
Strazzulla LC, Wang EH, Avila L, Sicco KL, Brinster N, Christiano AM, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15-24.
Dahabreh D, Jung S, Renert-Yuval Y, Bar J, Del Duca E, Guttman-Yassky E. Alopecia areata: current treatments and new directions. Am J Clin Dermatol. 2023;24(6):895-912.
Marahatta S, Agrawal S, Adhikari BR. Psychological impact of alopecia areata. Dermatol Res Pract. 2020;2020:8879343.
Torales J, Castaldelli-Maia JM, Ventriglio A, Almirón-Santacruz J, Barrios I, O’Higgins M, et al. Alopecia areata: a psychodermatological perspective. J Cosmet Dermatol. 2022;21(6):2318-23.
Maloh J, Engel T, Natarelli N, Nong Y, Zufall A, Sivamani RK. Systematic review of psychological interventions for quality of life, mental health, and hair growth in alopecia areata and scarring alopecia. J Clin Med. 2023;12(3):964.
Ahn D, Kim H, Lee B, Hahm DH. Psychological stress-induced pathogenesis of alopecia areata: autoimmune and apoptotic pathways. Int J Mol Sci. 2023;24(14):11711.
Almulhim NA, Alojail HY, Aljughayman MA, Almarri FH, Alsultan NH, Albash LA, et al. Awareness, beliefs, and psychological impact of patients with alopecia areata in Saudi Arabia: a multicenter study. Patient Prefer Adherence. 2024;18:2597-607.
Rudnicka L, Arenbergerova M, Grimalt R, Ioannides D, Katoulis AC, Lazaridou E, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38(4):687-94.
Putterman E, Patel DP, Andrade G, Harfmann KL, Hogeling M, Cheng CE, et al. Severity of disease and quality of life in parents of children with alopecia areata, totalis, and universalis: a prospective cross-sectional study. J Am Acad Dermatol. 2019;80(5):1389-94.
Downloads
Published
How to Cite
Issue
Section
